New Market Research Report: Neogenix Oncology, Inc. - Product Pipeline Analysis, 2013 Update
Neogenix Oncology, Inc. (NOI) is a clinical stage biotechnology company. The company develops therapeutic and diagnostic products for the early detection and treatment of cancer. Its antibody drug candidates and diagnostics are designed to detect and target the tumor without destroying healthy cells. NOI's lead product candidate includes Ensituximab, recognizes a particular epitope of tumor specific antigens from pancreatic or colorectal adenocarcinoma. The company also has two additional preclinical candidates, h16C3 and 31.1C, used to bind to tumor specific antigens...
View full press release